Shionogi Inc. is a U.S. subsidiary of Shionogi & Co., Ltd., a Japanese research-driven pharmaceutical company. Since 1878, we have been harnessing the full potential of science to address global health challenges. Over the past six decades, we have discovered several novel antibiotics and medications for HIV and influenza. Today, we're building on our scientific legacy by conducting ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. Beyond infectious disease,
our pipeline includes clinical programs in Fragile X syndrome, acute ischemic stroke, obesity and oncology. Learn more at
Shionogi.com.